3 completed, 2 recruiting, 2 terminated. 7 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 3, Recruiting 2, Terminated 2 |
| Phase 2 | 2 | Recruiting 2 |
Follow Metabolic Disorders: new trials by email Literature Review of Metabolic Disorders trials Research Report on Metabolic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of NAE on Polycystic Ovarian Syndrome (PCOS) Herbal Formulation, Metformin XR, Metformin 750 mg and herbal formulation 500 mg - Polycystic Ovarian Syndrome (PCOS), Infertility | Phase 1 | Completed | Jinnah Sindh Medical University | 116 | 2025-04-10 | 2026-06-22 |
| A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects AZD2693, Placebo - Metabolic Disorders, Non-alcoholic Steatohepatitis | Phase 1 | Completed | AstraZeneca | 73 | 2019-10-28 | 2021-11-26 |
| Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders RIC regimen, GVHD prophylaxis regimen - Severe Sickle Cell Disease, Bone Marrow Failure Syndromes | Phase 1 / Phase 2 | Recruiting | Washington University School of Medicine | 29 | 2017-03-20 | 2026-05-29 |
| A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders ProHema-CB Transplant - Metabolic Disorders | Phase 1 | Terminated | Fate Therapeutics | 1 | 2015-06-01 | 2018-10-10 |
| Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases BPX-501 and Rimiducid - Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis | Phase 1 | Terminated | Bellicum Pharmaceuticals | 1 | 2015-02-01 | 2024-03-25 |
| Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500 REGN1500, placebo - Metabolic Disorders | Phase 1 | Completed | Regeneron Pharmaceuticals | 55 | 2014-04-01 | 2015-09-30 |
| Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases Treatment Plan 1: Stratum 1, Treatment Plan 2: Strata 2, 3, or 4, GVHD Regimen A: UCB Recipients - Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders | Phase 1 / Phase 2 | Recruiting | Washington University School of Medicine | 220 | 2001-12-01 | 2026-09-16 |
Metabolic Diseases (7) · Hemoglobinopathies (3) · Anemia, Sickle Cell (2) · Anemia, Diamond-Blackfan (1) · Bone Marrow Failure Disorders (1) · Congenital Bone Marrow Failure Syndromes (1) · Diabetes Mellitus, Type 2 (1) · Dyskeratosis Congenita (1) · Dyslipidemias (1) · Fanconi Anemia (1) · Granulomatous Disease, Chronic (1) · Immune System Diseases (1) · Infertility (1) · Insulin Resistance (1) · Lymphohistiocytosis, Hemophagocytic (1)
Nutritional and Metabolic Diseases (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Genetic Diseases, Inborn (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Anemia (2) · Anemia, Hemolytic (2) · Anemia, Hemolytic, Congenital (2) · Bone Marrow Diseases (2) · Digestive System Diseases (2) · Endocrine System Diseases (2) · Glucose Metabolism Disorders (2) · Lipid Metabolism Disorders (2) · Adnexal Diseases (1) · Anemia, Aplastic (1)
Metformin (1) · evinacumab (1)
Washington University School of Medicine (2) · AstraZeneca (1) · Bellicum Pharmaceuticals (1) · Fate Therapeutics (1) · Jinnah Sindh Medical University (1) · Regeneron Pharmaceuticals (1)
United States (6) · Canada (1) · Pakistan (1)
Shalini Shenoy, MD (2) · Chris Storgard, MD (1) · David Han, MD (1)
PMID 15592491, PMID 16990602, PMID 18026148, PMID 18500373, PMID 26348869, PMID 31242752, PMID 32813873, PMID 39798707